INOVIO Pharmaceuticals (INO) Stock Continues Up On COVID-19 Update

Inovio Pharmaceuticals INO Stock News

INOVIO Pharmaceuticals Inc (NASDAQ: INO) is heading up in the market this morning, following up on the impressive gains that we saw in the stock yesterday. The gains come after the company announced an update with regard to clinical testing of INO-4800 for the prevention of COVID-19 infection. Here’s what’s happening:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

INO Climbs After Dosing First Patient With COVID-19 Vaccine

In the press release, INOVIO Pharmaceuticals said that it has begun Phase 1 clinical testing of its COVID-19 vaccine candidate in healthy volunteers. In fact, the first dosing of a patient was planned to take place yesterday.

In the Phase 1 clinical study, the company plans on enrolling up to 40 healthy adult volunteers. The company said tht last week, supplies needed for the study arrived, giving the company everything it needed to move forward.

As such, INO said that participants in the study will receive two doses of INO-4800 four weeks apart. Moreover, initial immune responses and safety data from the study is expected to be released this coming summer.

In the release, the company said that preclinical results for its COVID-19 vaccine have been consistent with its completed Phase 1 vaccine study for MERS, also caused by a coronavirus. This is promising news as the company’s MERS vaccine has shown strong signs of efficacy.

In the release, the company said that once it receives safety and immunogenicity data from the Phase 1 study, it plans on quickly advancing INO-4800 to Phase 2. At this point, the company will also aggressively scale up manufacturing with a goal of bringing the vaccine to patients on a commercial level by the end of the year.

In a statement, Dr. J. Joseph Kim, President and CEO at INO, had the following to offer:

This is a significant step forward in the global fight against COVID-19. Without a new safe and effective vaccine, the COVID-19 pandemic is likely to continue to threaten lives and livelihoods. It also demonstrates the power of our DNA medicines platform to rapidly develop and advance a vaccine for COVID-19 into Phase 1 clinical testing. Our dedicated team of staff, partners and funders have been mobilized since the genetic sequence of the virus became available in early January and continues to work around the clock to ensure that we are rapidly advancing INO-4800 through this Phase 1 study towards planned efficacy trials.

This News Is Overwhelmingly Exciting

At the end of the day, the news issued by INOVIO Pharmaceuticals is massive. First and foremost, the company is sticking with the plan set forth when it first announced that it had a vaccine candidate ready for testing. This plan is a rapid push for commercialization by the end of the year.

It’s also worth paying attention to the fact that preclinical data is consistent with INO-4700, a very promising MERS vaccine. Due to the fact that MERS and COVID-19 are caused by coronaviruses, there’s a strong chance that INO-4800 will prove to be incredibly effective against the novel coronavirus.

With experience in vaccinating against coronavirus infections, the fact that the company is well ahead of the competition, and the fact that the company is expecting to launch the vaccine by the end of the year, INO is a stock that’s well worth watching closely!

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Don’t Miss The Next Big Story

Join our free mailing list below to receive real-time news alerts!

Subscribe Today!

* indicates required

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.